leadf
logo-loader
CSE:BETR OTCQB:BETRF

BetterLife Pharma Inc

Receive alerts
Market:
CSE
Market Cap:
$23.75 m
Price
0.28 CAD
Change
-3.45%
52 weeks high
2.27
52 weeks low
0.23

In brief

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next generation psychedelic products for the treatment of mental disorders. Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.

Snapshot

CEO Ahmad Doroudian has said the firm is “aggressively developing” next generation psychedelic products like TD-0148A, to become a leader in a market with a projected $6.85 billion value by 2027

Insight Widest with the analysis, Proactive gives perspectives that others don't.

BetterLife Pharma on promising path with Altum merger and Phase 2 trial of AP-003 drug to fight coronavirus

The group’s CEO Ahmad Doroudian expects the AP-003 Phase 2 trial to be completed in the next three-to-six months, and approved under emergency use authorization

on 15/7/20